Oral Fluid Testing Established for Pertussis
|
By LabMedica International staff writers Posted on 19 Jun 2014 |

Image: Electron micrograph of the bacterium Bordetella pertussis, the causative agent of pertussis (Photo courtesy of Sanofi Pasteur).
Existing surveillance systems for pertussis or whooping cough are inadequate and tend to be biased toward identifying severe cases in infants, as reflected by extremely high reported incidence for this age group.
Bordetella pertussis, the causative agent of pertussis, has been isolated from the nasopharynx by use of conventional microbiological techniques. However, culture requires that a specimen be collected early in the illness and might lack sensitivity because the organism is delicate, and any delay in processing specimens can reduce the probability of isolation.
Microbiologist at Public Health England (Colindale, London, UK) have introduced a new oral fluid testing service that was pilot tested throughout England and Wales. When a case was reported, if the diagnosis had not been confirmed by culture, polymerase chain reaction (PCR), or serologic testing, oral fluid sampling kits were mailed either directly to the patients or to the parents/guardians of patients, as the kit was suitable for use at home, or to their general practitioner. The sampling kit contained an ORACOL saliva collection swab (Malvern Medical Developments Ltd, Worcester, UK).
Oral fluid was eluted from each swab and tested for immunoglobulin G (IgG) against pertussis toxin by enzyme-linked immunoassay (ELISA). During the oral fluid pilot testing period, 2,756 oral fluid kits were sent, 2,587 clinical cases were reported, and 2,443 cases of pertussis were confirmed by at least one laboratory method. Of these confirmed cases, 751 were confirmed by oral fluid testing plus or minus other methods and 591 (24% of all cases) were confirmed by oral fluid testing only, which increased laboratory ascertainment of pertussis by 32%, and a maximal increase of 124% occurred among children 5 to 9 years of age.
The authors concluded that the introduction of serologic testing followed by oral fluid testing has successively narrowed the gap in surveillance for pertussis in England and Wales. Patients whose pertussis was confirmed by oral fluid testing were least likely to be hospitalized, suggesting that milder community cases were being confirmed by this method. Oral fluid testing is an easily administered, noninvasive surveillance tool that could further our understanding of pertussis epidemiology and thereby contribute to decisions on vaccination strategies. The study was published in the June 2014 issue of the journal Emerging Infectious Diseases.
Related Links:
Public Health England
Malvern Medical Developments Ltd.
Bordetella pertussis, the causative agent of pertussis, has been isolated from the nasopharynx by use of conventional microbiological techniques. However, culture requires that a specimen be collected early in the illness and might lack sensitivity because the organism is delicate, and any delay in processing specimens can reduce the probability of isolation.
Microbiologist at Public Health England (Colindale, London, UK) have introduced a new oral fluid testing service that was pilot tested throughout England and Wales. When a case was reported, if the diagnosis had not been confirmed by culture, polymerase chain reaction (PCR), or serologic testing, oral fluid sampling kits were mailed either directly to the patients or to the parents/guardians of patients, as the kit was suitable for use at home, or to their general practitioner. The sampling kit contained an ORACOL saliva collection swab (Malvern Medical Developments Ltd, Worcester, UK).
Oral fluid was eluted from each swab and tested for immunoglobulin G (IgG) against pertussis toxin by enzyme-linked immunoassay (ELISA). During the oral fluid pilot testing period, 2,756 oral fluid kits were sent, 2,587 clinical cases were reported, and 2,443 cases of pertussis were confirmed by at least one laboratory method. Of these confirmed cases, 751 were confirmed by oral fluid testing plus or minus other methods and 591 (24% of all cases) were confirmed by oral fluid testing only, which increased laboratory ascertainment of pertussis by 32%, and a maximal increase of 124% occurred among children 5 to 9 years of age.
The authors concluded that the introduction of serologic testing followed by oral fluid testing has successively narrowed the gap in surveillance for pertussis in England and Wales. Patients whose pertussis was confirmed by oral fluid testing were least likely to be hospitalized, suggesting that milder community cases were being confirmed by this method. Oral fluid testing is an easily administered, noninvasive surveillance tool that could further our understanding of pertussis epidemiology and thereby contribute to decisions on vaccination strategies. The study was published in the June 2014 issue of the journal Emerging Infectious Diseases.
Related Links:
Public Health England
Malvern Medical Developments Ltd.
Latest Microbiology News
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
- Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
- Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
- Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
- Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







